Women with a history of migraine are at increased risk for developing hypertension.
Avoidance can lead to headache disability by reducing pain thresholds and preventing pain habituation.
The characteristics of migraine may change throughout a woman's reproductive stages, and may require different treatment strategies.
Qudexy XR is already approved for use as initial monotherapy and adjunctive therapy to treat certain types of seizures.
A significant decrease in migraine frequency was observed, but it is not clear how large a role placebo effect plays in treatment response.
Future research should focus on whether cogniphobia can be a modifiable factor in the treatment of patients with migraine.
Persistent asthma was found to be associated with an increased frequency of migraine.
Migraine in pregnancy may warrant early referral to a neurologist and more intensive surveillance as a result of increased adverse birth events.
The use of combined hormonal contraceptives significantly increases the risk of ischemic stroke in women with migraine with aura but not in women with migraine without aura.
Cognitive behavioral therapy provides sustained relief from pediatric migraine with few to no adverse effects.
Women with a history of migraine headache had a more than 2-fold increased risk of stroke over a 6-year follow-up period.
No significant difference in reduction of headache days was observed between the treatment groups and placebo.
The study results suggest that headaches are a growing burden on patients and the health care system.
Eighty-one percent of patients deemed ziprasidone effective in reducing migraine severity.
The 6 mg dose will remain available.
Acupuncture, neurostimulation, and other alternative treatments have been associated with up to a 50% reduction in headache days.
Abstinence from caffeine was independently associated with excellent acute treatment efficacy.
Two studies on the therapy were presented at the American Heart Association's Council on Hypertension 2016 Scientific Sessions.
Combined treatment approaches are more beneficial than single approaches for chronic pain conditions like migraine.
The drug's pediatric exclusivity expires in March 2017.
Clinicians need to remain vigilant when prescribing tramadol, as its concurrent use with opioids poses a risk of serotonin toxicity.
Neurologists should collaborate with other specialties in order to increase awareness of migraine prevalence in men.
New findings suggest shared genetic etiology vs causal relationship in comorbid migraine and depression.
Risk of VTE was only observed in patients with migraine with aura, suggesting a mechanistic link between the 2 conditions.
The new device is three-quarters the size of the original.
An earlier study examined the efficacy of 2 mg folic acid.
Fiber optic light at blue and yellow wavelengths can respectively activate and inhibit neurons expressing light-sensitive ion channels
More than 50% of patients with migraine are treated with opioids in the ED despite known risks.
Patients in both groups were satisfied with their care.
Huma Sheikh, MD, discusses some of her top picks from presentations made at the 2016 AHS annual meeting.
Neurology Advisor Articles
- Addressing Rare Headache Disorders: Acute Confusional Migraine
- Organic Solvents Plus Genetics May Increase Risk of Multiple Sclerosis
- No Significant Clinical Differences Between Cluster Headaches With and Without Aura
- Co-Prescription of Opioids and Antidepressants Prevalent in Migraine
- Deep Brain Stimulation May Slow Rest Tremor Progression in Parkinson Disease
- Herpesvirus Abundant in Alzheimer Disease Brain, New Study Finds
- Patients' Preferences for Physician Attire Linked to Perception of Care
- Weighing the Risks of Deep Brain Stimulation
- Grey Matter Atrophy Sequence in Multiple Sclerosis Phenotypes
- Higher Vitamin D Levels Associated With Fewer Lesions in Multiple Sclerosis
- Screening Tool Differentiates Progressive Supranuclear Palsy and Parkinson Disease
- Risk Factors for Impulse Control Behaviors in Parkinson Disease
- Cardiac Pathology in SUDEP Compared With Sudden Arrhythmic or Traumatic Deaths
- 11.2% of U.S. Adults Aged ≥45 Report Subjective Mental Decline
- AMA Aims to Boost Affordability of ACA Marketplace Plans